VHI Vitalhub Corp.
Vitalhub Corp., together with its subsidiaries, provides technology and software solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. The company offers patient flow, operational visibility, and patient journey optimization solutions for hospital and integrated health environments, including SHREWD, Intouch with Health, Strata Health, MedCurrent, Beautiful Information, My Pathway, BookWise Solutions, Jayex Acute, MCAP, and Oculys. It also provides electronic healthcare record, case management, care coordination, and optimization solutions to inpatient/outpatient care providers, long-term care, and community and social services focused organizations, such as TREAT, CaseWORKS, clarity, Community Data Solutions, S12, B Care, DOCit, hicom, Clarity Healthcare Solutions, and Pirouette. In addition, the company offers a workforce automation and compliance suite that integrates and centralizes workforce and compliance data, which includes Hicom, Premier IT, and BookWise. Vitalhub Corp. was founded in 2010 and is headquartered in Toronto, Canada.…
Industry Peers
Health Information ServicesKey Statistics
About Vitalhub (TSE: VHI)
›
Vitalhub (TSE: VHI) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 700 employees.
The shares were at 6.360 CAD on 19 November 2026, down 29.1% over 52 weeks. Its 52-week range is 6.300 CAD to 9.770 CAD, and it trades at the bottom of that range.
At a market capitalisation of 402.84M CAD, it trades at 37.4 times trailing earnings and 20.5 times forward earnings. The median trailing P/E of its 14 largest Health Information Services peers is 42.1, a discount of 11% for VHI.
Vitalhub reports return on equity of 2.3%, an operating margin of 12.5% and flat revenue year over year.
It holds more cash than debt, a net cash position of 125.78M CAD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 10.52 CAD is 65.5% above the current price. The next earnings report is expected on 18 March 2027.